According to a report in the Financial Times, the protein vascular endothelial growth factor may cause the abnormal blood vessel proliferation in diabetic retinopathy.
The article goes on to say that high levels of VEGF are found in the eyes of patients with this complication of diabetes. The protein was first isolated as a possible route for the inhibition of angiogenesis associated with tumor growth. Following further work showing that the protein regulates the formation of blood vessels in the developing rat retina, the next step is the development of a drug to inhibit the production of VEGF.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze